ENDRA Life Sciences (ENDRA Life Sciences) Total Liabilities : $1.10 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences Total Liabilities?

ENDRA Life Sciences's Total Liabilities for the quarter that ended in Dec. 2023 was $1.10 Mil.

ENDRA Life Sciences's quarterly Total Liabilities increased from Jun. 2023 ($2.31 Mil) to Sep. 2023 ($2.41 Mil) but then declined from Sep. 2023 ($2.41 Mil) to Dec. 2023 ($1.10 Mil).

ENDRA Life Sciences's annual Total Liabilities declined from Dec. 2021 ($2.09 Mil) to Dec. 2022 ($2.07 Mil) and declined from Dec. 2022 ($2.07 Mil) to Dec. 2023 ($1.10 Mil).

ENDRA Life Sciences Total Liabilities Historical Data

The historical data trend for ENDRA Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences Total Liabilities Chart

ENDRA Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.42

1.60

2.09

2.07

1.10

ENDRA Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															2.07	2.16	2.31	2.41	1.10

ENDRA Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ENDRA Life Sciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.903	+	(0.192	+	-5.5511151231258E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.10

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	6.754	-	5.659
	=	1.10

ENDRA Life Sciences's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.903	+	(0.192	+	-5.5511151231258E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.10

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	6.754	-	5.659
	=	1.10

ENDRA Life Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ENDRA Life Sciences (ENDRA Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570

Website

https://www.endrainc.com

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Executives

Michael Milos Thornton	officer: Chief Technology Officer	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman	director	C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon	director, officer: Chief Executive Officer	430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova	officer: Senior Director, Finance	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells	officer: Chief Financial Officer	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc	10 percent owner	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	10 percent owner	1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105